IP Library › Granted Patent US 8,404,445
Granted Patent B2
US 8,404,445 · App. 12/570,897 · Granted Mar 26, 2013

Antibody libraries

Inventors: Chung-Ming Hsieh (Newton, MA); Yuliya A. Kutskova (Northborough, MA); John E. Memmott (Framingham, MA)
Assignee: AbbVie Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,404,445
App. No.
12/570,897
Granted
Mar 26, 2013
Kind
B2
Abstract

The present invention features improved in vitro RNA display libraries to allow reliable expression and selection of scFv antibody molecules from expression libraries. The scFv antibody libraries of the invention contain an optimized, shortened inter-domain linker that improves expression scFv antibody expression. The scFv antibody libraries also include short nucleic acid barcodes that allow for identification of individual library clones, libraries or subsets thereof. Primers for generating, amplifying and spectratyping the scFv antibody libraries of the invention are also provided.

Claims (47)

1. A method of producing a polynucleotide library for expression of single chain antibodies (scFv) comprising:

providing a polynucleotide composition, wherein at least a portion of the polynucleotides in said composition comprise at least one open reading frame encoding an antibody variable domain; and,

amplifying a plurality of polynucleotides encoding antibody variable domains with one or more oligonucleotides comprising the oligonucleotide sequence(s) of SEQ ID NO: 133 or SEQ ID NO: 140, thereby producing a polynucleotide library.

2. The method of claim 1 , wherein the one or more oligonucleotide(s) are selected from the group consisting of SEQ ID NO: 134, 135, 136, 137, 138, 139, 140, 145, 146, 166, 183, 184, 185, 186, 187, 188, 189 and 190, or combinations thereof.

3. The method of claim 1 , wherein the one or more oligonucleotide(s) are selected from the group consisting of SEQ ID NOs 133, 141, 142, 143, 144, 147, 163 and 167, or combinations thereof.

4. The method of claim 1 , said library comprising a repertoire of sequences encoding heavy chain variable domains and light chain variable domains, wherein each member of said library contains an open reading frame comprising a heavy chain variable domain, a light chain variable domain, and a linker region.

5. The method of claim 4 , wherein the linker region encodes less than 20 amino acids.

6. The method of claim 4 , wherein the linker region encodes 15 amino acids.

7. The method of claim 4 , wherein each member of said library further comprises a promoter operably linked to the open reading frame.

8. The method of claim 7 , wherein said promoter is a promoter selected from the group consisting of T7, SP6, and T3.

9. The method of claim 8 , wherein said promoter is a T7 promoter.

10. The method of claim 4 , wherein each member of said library further comprises a 5′ untranslated region (5′UTR) capable of enhancing transcription of a gene to which it is operably linked.

11. The method of claim 10 , wherein said 5′UTR is a Tobacco Mosaic Virus 5′UTR or active fragment thereof.

12. The method of claim 4 , wherein each member of said library further comprises a polyadenine sequence.

13. The method of claim 4 , wherein each member of said library further comprises a nucleic acid barcode.

14. The method of claim 13 , wherein said nucleic acid barcode comprises 8 nucleotides.

15. The method of claim 4 , wherein each member of said library further comprises a nucleic acid sequence encoding an epitope tag.

16. The method of claim 15 , wherein said nucleic acid sequence is part of the linker region of the scFv.

17. The method of claim 4 , wherein each member of said library further comprises a nucleic acid sequence encoding an antibody constant region or fragment thereof.

18. The method of claim 4 , wherein each member of said library further comprises a ribosome pause sequence.

19. The method of claim 4 , wherein each member of said library further comprises a peptide acceptor.

20. The method of claim 19 , wherein the peptide acceptor is covalently attached via a linker comprising a Psoralen C6 molecule.

21. The method of claim 20 , wherein the linker is 5′ (Psoralen C6) 2′Ome (U AGC GGA UGC) (SEQ ID NO: 211) XXX XXX CC (Puromycin), wherein X is a triethylene glycol linker or PEG-150 and CC is a DNA backbone.

22. An oligonucleotide comprising the oligonucleotide sequence of SEQ ID NO: 133.

23. The oligonucleotide of claim 22 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 141.

24. The oligonucleotide of claim 22 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 142.

25. The oligonucleotide of claim 22 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 143.

26. The oligonucleotide of claim 22 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 144.

27. The oligonucleotide of claim 22 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 147.

28. The oligonucleotide of claim 22 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 167.

29. An oligonucleotide comprising the oligonucleotide sequence of SEQ ID NO: 140.

30. The oligonucleotide of claim 29 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 134.

31. The oligonucleotide of claim 29 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 135.

32. The oligonucleotide of claim 29 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 136.

33. The oligonucleotide of claim 29 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 137.

34. The oligonucleotide of claim 29 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 138.

35. The oligonucleotide of claim 29 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 139.

36. The oligonucleotide of claim 29 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 146.

37. The oligonucleotide of claim 29 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 166.

38. The oligonucleotide of claim 29 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 183.

39. The oligonucleotide of claim 29 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 184.

40. The oligonucleotide of claim 29 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 185.

41. The oligonucleotide of claim 29 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 186.

42. The oligonucleotide of claim 29 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 187.

43. The oligonucleotide of claim 29 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 188.

44. The oligonucleotide of claim 29 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 189.

45. The oligonucleotide of claim 29 , wherein the oligonucleotide comprises the oligonucleotide sequence of SEQ ID NO: 190.

Assignments (3)
CHANGE OF NAME Recorded Feb 26, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 029875/0187 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2010
From: HSIEH, CHUNG-MING; KUTSKOVA, YULIYA A.; MEMMOTT, JOHN E.
To: ABBOTT LABORATORIES
Reel/Frame 024115/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2010
From: HSIEH, CHUNG-MING; KUTSKOVA, YULIYA A.; MEMMOTT, JOHN E.
To: ABBOTT LABORATORIES
Reel/Frame 023983/0364 →
Continuity (2)
Provisional Application 61101483 · Sep 30, 2008
Related Publication 20100099103A1 · Apr 22, 2010